This Article Full Text (PDF) References Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Alert me to new issues of the journal Add to Saved Citations Download to citation manager Request Permissions Request Reprints Add to My Marked Citations Citing Articles Citing Articles via Google Scholar Citing Articles via Scopus Google Scholar Articles by Wiggins, B. S. Articles by Spinler, S. Search for Related Content Social Bookmarking                   What's this?

Antiplatelet and Antithrombin Therapy for Early Management of Acute Coronary Syndromes

Heart Center, University of Virginia Health System, University of Virginia School of Nursing and School of Medicine, Charlottesville, bsw4v{at}virginia.edu

Sarah Spinler, PharmD, FCCP

Philadelphia College of Pharmacy, University of the Sciences in Philadelphia, University of Pennsylvania, Department of Medicine, Cardiovascular Division, Philadelphia

Acute coronary syndromes (ACS) are defined as either unstable angina (UA), non-ST-segment elevation myocardial infarction (NSTEMI), or ST-segment elevation myocardial infarction (STEMI). Their management is continuously evolving in terms of pharmacologic therapy. The usual cause of ACS is the disruption of an atherosclerotic plaque leading to formation of a thrombus within a coronary artery. Initial antiplatelet and antithrombin therapy for patients with ST-segment elevation (STE) ACS includes aspirin and unfractionated heparin (UFH). Patients presenting to the hospital early may undergo percutaneous intervention (PCI) with administration of additional medications such as clopidogrel and abciximab or may receive a fibrinolytic agent. Patients with non-ST-segment elevation (NSTE) ACS receive aspirin, clopidogrel, either a low-molecular-weight heparin or UFH, and, in selected patients, a glycoprotein (GP) IIb/IIIa receptor blocker. All of these agents have shown benefit when administered to patients with ACS, but results vary depending on the type of syndrome, timing of administration, and patient’s overall risk. Their mechanism of action, role in ACS, clinical practice recommendations, adverse effects, and monitoring are reviewed. Some inherent limitations to agents such as aspirin and UFH require the need for newer treatment approaches. Therefore, newer classes of drugs such as the direct thrombin inhibitor bivalirudin and the selective factor Xa inhibitor fondaparinux are being explored as alternatives to heparins for ACS management.

Key Words: Acute coronary syndromes • antiplatelet • clopidogrel • aspirin • low-molecular-weight heparin • enoxaparin • UFH • bivalirudin • abciximab • eptifibatide

Journal of Pharmacy Practice, Vol. 17, No. 5, 347-369 (2004)
DOI: 10.1177/0897190004271778


CiteULike    Connotea    Del.icio.us    Digg    Reddit    Technorati    What's this?